You are here: Industry Insights > Market News > Lupin launches authorised generic version of Apriso

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Lupin launches authorised generic version of Apriso

expresspharmaMay 19, 2020

Tag: mesalamine , ulcerative colitis , lupin , Apriso

Favorites

Mesalamine Extended-Release Capsules 0.375 g (the authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.

Pharma major Lupin announced the launch of authorized generic version of Bausch Health’s Apriso (Mesalamine Extended-Release Capsules 0.375 g) in the U.S.

Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.

Mesalamine Extended-Release Capsules 0.375 g. Apriso had an annual sales of approximately USD 290 million in the US (IQVIA MAT March 2020).

Previous:AZ/Daiichi Sankyo's Enhertu picks up third breakthrough designation

Next:Ashwagandha can be effective preventive drug against coronavirus: IIT Delhi research

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

The expanded collaboration includes increasing adoption of the NVIDIA Clara suite of AI-powered computing platforms, software, and services in the Sartorius ecosystem.

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

Lupin launches authorised generic version of Apriso | Pharmasources.com

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

Nucleic Acid Medicines Manufacture, Round 2 call.

Lupin launches authorised generic version of Apriso

Related News

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

You may like